Topics
HPV vaccineChemical substance
Vaccine price is one of the most influential parameters in economic evaluations of HPV vaccination programmes. Vaccine tendering is a cost-containment method widely used by national or regional health authorities, but information on tender-based HPV vaccine prices is scarce
This study reviews the current challenges in the economic evaluation of vaccines with a focus on Eur...
Despite an effective screening programme, 600-700 women are still diagnosed with cervical cancer in ...
Despite an effective screening programme, 600-700 women are still diagnosed with cervical cancer in ...
Vaccine price is one of the most influential parameters in economic evaluations of HPV vaccination p...
Background: Vaccine price is one of the most influential parameters in economic evaluations of HPV v...
Background: Vaccination against HPV presents a new primary prevention strategy against cervical canc...
Abstract: Background: Vaccination against HPV presents a new primary prevention strategy against cer...
AbstractBackgroundNearly all of the 500,000 new cases of cervical cancer and 270,000 deaths occur in...
The total cost of HPV-related diseases accounts for euro 200-250 million of which euro 210 million i...
Human papillomavirus (HPV) is responsible for almost all of the 570,000 new cases of cervical cancer...
In the Netherlands, low cervical cancer incidence and mortality rates might limit the cost-effective...
BACKGROUND: This commentary discusses key issues for health economic evaluation and modelling, appli...
From 2012 to 2016, Gavi, the Vaccine Alliance, provided support for countries to conduct small-scale...
In this study, the potential price for a therapeutic vaccine against Human Papilloma Virus (HPV)-16 ...
This study reviews the current challenges in the economic evaluation of vaccines with a focus on Eur...
This study reviews the current challenges in the economic evaluation of vaccines with a focus on Eur...
Despite an effective screening programme, 600-700 women are still diagnosed with cervical cancer in ...
Despite an effective screening programme, 600-700 women are still diagnosed with cervical cancer in ...
Vaccine price is one of the most influential parameters in economic evaluations of HPV vaccination p...
Background: Vaccine price is one of the most influential parameters in economic evaluations of HPV v...
Background: Vaccination against HPV presents a new primary prevention strategy against cervical canc...
Abstract: Background: Vaccination against HPV presents a new primary prevention strategy against cer...
AbstractBackgroundNearly all of the 500,000 new cases of cervical cancer and 270,000 deaths occur in...
The total cost of HPV-related diseases accounts for euro 200-250 million of which euro 210 million i...
Human papillomavirus (HPV) is responsible for almost all of the 570,000 new cases of cervical cancer...
In the Netherlands, low cervical cancer incidence and mortality rates might limit the cost-effective...
BACKGROUND: This commentary discusses key issues for health economic evaluation and modelling, appli...
From 2012 to 2016, Gavi, the Vaccine Alliance, provided support for countries to conduct small-scale...
In this study, the potential price for a therapeutic vaccine against Human Papilloma Virus (HPV)-16 ...
This study reviews the current challenges in the economic evaluation of vaccines with a focus on Eur...
This study reviews the current challenges in the economic evaluation of vaccines with a focus on Eur...
Despite an effective screening programme, 600-700 women are still diagnosed with cervical cancer in ...
Despite an effective screening programme, 600-700 women are still diagnosed with cervical cancer in ...
Add to ORKG